Combined treatment of stage IV melanoma patients with amifostine and fotemustine - A pilot study

Melanoma Research

Volumn 8, Issue 2, 1998, Pages 166-169

  Mohr, P ^a   Makki, A ^a   Breitbart, E ^a   Schadendorf, D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bone marrow toxicity; Brain metastases; Chemoprotection

Indexed keywords

AMIFOSTINE; FOTEMUSTINE;

ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MELANOMA; NAUSEA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031898337     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199804000-00011     Document Type: Article

References (16)

1. Spencer CM, Goa KL. Amifostine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995; 50: 1001-1031.
2. Boote DJ, Barnardo P, Banzet P, et al. Evaluation of fotemustine in metastatic malignant melanoma (MMM): a phase II study. ECCO V, London, 1989: P-0611.
3. Khajat D, Avril MF, Gerard B, Bertrand P, Bizzari JP, Cour V. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma Res 1992; 2: 147-151.
4. Merimsky O, Inbar M, Gerard B, Chaintchik S. Fotemustine: an advance in the treatment of metastatic malignant melanoma. Melanoma Res 1992; 2: 401-406.
5. Mohr P, Weichenthal M, Stephan U, Kowalzick K, Hossfeld DK, Breitbart EW. Fotemustine with or without Interferon α-2b in the treatment of advanced malignant melanoma. A comparison of two clinical trials. Fifth World Conference on Cancer of the Skin, Berlin, 1993. Melanoma Res 1993; 3(suppl 2): 31.
6. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990; 66: 1873-1878.
7. Boazit C, Breau JL, Morere JF, Israel L. Cerebral metastasis of malignant melanoma. Bull Cancer 1991; 78: 347-353.
8. Treskes M, Nijtmans LGJ, Frichtinger-Schpmann AMJ, et al. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison of the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 1992; 43: 1013-1019.
9. Meulemans A, Giroux B, Hannoun P, et al. Permeability of two nitrosoureas, carmustine and fotemustine, in rat cortex. Chemotherapy 1989; 35: 313-319.
10. Van der Vijgh WJF, Godefridus JP Protection of normal tissue from cytotoxic effects of chemotherapy and radiation by amifostlne (Ethyol): preclinical aspects. Semin Oncol 1994; 21(suppl 11): 2-7.
11. Bröcker EB, Bohndorf W, Kämpgen E, Trcka J, Messer P, Tilgen W, Engenhart K, Flentje M. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report of a pilot study. Melanoma Res 1996; 6: 399-401.
12. Capizzi RL, Scheffler BJ, Schein PS. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy. Cancer 1993; 72: 3495-3501.
13. Yuhas JM. Active versus passive absorbtion kinetics as basis for selective protection of normal tissue by S-2-(3-aminopropylamino)ethylphosphorothioic acid. Cancer Res 1980; 40: 1519-1524.
14. Kemp G, Rose P, Lurian J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomised control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 7: 2101-2112.
15. Treskes M, Boven E, Van de Loosdrecht AA, et al. Effects of modulating agent WR-2721 on myelotoxicity and antitumor activity of carboplatin-treated mice. Eur J Cancer 1992; 30: 183-187.
16. Jacquillat C, Khayat D, Banzet P. et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990; 25: 263-266.